AI Drug Discovery for Pharma and Biotech

Drug discovery

23

drugs

With orphan designations

Overview

Polycythemia vera (PV) is a chronic myeloproliferative neoplasm characterized by somatic JAK2 mutations (>95% of cases), erythrocytosis, and thrombotic risk due to blood hyperviscosity [1][2][6]. Diagnosis requires elevated hemoglobin/hematocrit, JAK2 mutation, and bone marrow panmyelosis per WHO criteria [2][5]. Management focuses on thrombosis prevention through hematocrit control (<45% via phlebotomy), low-dose aspirin, and cytoreductive therapy for high-risk patients [8][13][18].

Population

  • Prevalence: 44–57 per 100,000, with median diagnosis age >60 years; slight male predominance [1][12][15].

  • ~95% have JAK2 V617F or exon 12 mutations driving uncontrolled erythropoiesis [2][6][12].

Burden

  • Thrombosis: 26% 20-year risk of arterial/venous events (e.g., stroke, pulmonary embolism) [5][12].

  • Symptoms: Fatigue (50–80%), pruritus (40–60%), splenomegaly (35–50%), and erythromelalgia impair quality of life [4][9][16].

  • Progression: 10–15% develop post-PV myelofibrosis; 3–5% transform to acute leukemia [2][5][12].

Therapies

  • First-line: Phlebotomy + aspirin; hydroxyurea or peginterferon for high-risk patients (age >60 or thrombosis history) [5][8][13].

  • Second-line: Ruxolitinib (JAK inhibitor) for hydroxyurea-resistant/intolerant cases; ropeginterferon alfa-2b for durable responses [3][18][19].

  • Emerging therapies: Rusfertide (hepcidin mimetic) reduces phlebotomy dependence in clinical trials [3][14].

Categories: rare hematological diseases, rare neoplastic diseases, rare transplant-related disorders

Research Papers

1,840 drug discovery papers about Polycythemia vera, with 2 first-in-class and 35 next-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:

1,840 drug discovery papers about Polycythemia vera, with 2 first-in-class and 35 next-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:

categories:

Small molecules

small molecules
2026-09-30 | Masked polycythaemia vera presenting with extensive splanchnic venous thrombosis and mesenteric ischaemia.

Splanchnic venous thrombosis (SVT) is a potentially catastrophic manifestation of polycythaemia vera (PV). We report a woman in her 60s with masked PV who had been managed for 5 years with intermittent phlebotomy and aspirin without haematology referral, molecular testing or cytoreductive therapy. Chronic iron deficiency masked erythrocytosis, delaying diagnosis. She presented with extensive thrombosis involving the portal, splenic and superior mesenteric veins complicated by mesenteric ischaemia requiring exploratory laparotomy, jejunal resection and ileostomy. Bone marrow biopsy and JAK2 V617F testing confirmed PV. Therapeutic anticoagulation was initiated with enoxaparin and subsequently transitioned to apixaban, while hydroxyurea achieved sustained haematologic control. Interval imaging demonstrated thrombus regression with persistent cavernous transformation. Given ongoing portal hypertension, oesophageal varices, occasional mild ostomy bleeding and low body weight, anticoagulation was continued indefinitely at reduced intensity with apixaban 2.5 mg twice daily. At 21-month follow-up, the patient remained free of recurrent thrombosis and major bleeding.

Open article ↗



2026-09-01 | Diagnosis and Management of Polycythemia Vera Complicated by Cerebral Infarction and Subdural Hematoma: A Case Report

ABSTRACT Myeloproliferative neoplasms are hematologic disorders associated with increased thrombotic and hemorrhagic risk. However, they are often underrecognized in patients presenting with cerebrovascular events. We report the case of a 70‐year‐old man who developed an acute cerebral infarction in the left temporal lobe accompanied by limb weakness. Neuroimaging revealed multiple cerebrovascular stenoses and widespread atherosclerotic vascular disease. During follow‐up, he developed a subdural hematoma. Further evaluation demonstrated persistent blood count abnormalities and splenomegaly. Bone marrow biopsy revealed a hypercellular marrow with trilineage proliferation (panmyelosis), characterized by prominent erythroid, granulocytic, and megakaryocytic lineages. Molecular testing revealed the Janus kinase 2 Valine 617 Phenylalanine mutation. Combined with elevated hemoglobin levels, these findings fulfilled the diagnostic criteria for polycythemia vera in the fifth edition of the World Health Organization Classification of Haematolymphoid Tumors. This case highlights that coexisting ischemic and hemorrhagic cerebrovascular events with unexplained hematologic abnormalities or splenomegaly should prompt Janus kinase 2 mutation screening and bone marrow examination to enable early diagnosis of myeloproliferative neoplasm and prevent further complications.

Open article ↗



2026-09-01 | Incidence, prevalence, and survival outcomes of patients with myeloproliferative neoplasms in the United States: a Surveillance, Epidemiology, and End Results (SEER) database analysis, years 2000-2021.

Myeloproliferative Neoplasms (MPNs) are rare hematologic neoplasms. The epidemiology and outcomes of these rare neoplasms warrant an update considering new diagnostic tools and advances in treatment options. NCI's Surveillance, Epidemiology and End Results (SEER)-17 registries were interrogated to analyze adult patients diagnosed with MPN [ICD-O-3 codes: polycythemia vera (PV) 9950/3, essential thrombocythemia (ET) 9962/3, primary myelofibrosis (PMF) 9961/3 and chronic myeloid leukemia (CML) 9875/3] during the years 2000 to 2021. Data of 63,242 (ET, n = 24,172; PV, n = 23,456; PMF, n = 6131; CML, n = 9483) patients were analyzed. The overall incidence rate (IR) for ET, PV, PMF and CML was 1.8, 1.7, 0.5 and 0.7 per 100,000 person-years, respectively. The incidence of ET, PV, and MF increased with age, and the majority of cases were seen after the age of 50. 5-year Relative Survival (RS) for PMF was 50.9% in 2009, to 57.4% in 2013 and 60.6% in 2016. The median overall survival (OS) was 152 months for ET, 150 months for PV, 48 months for PMF, and 202 months for CML. Advancing age was associated with adverse survival across MPN subtypes. Survival of patients with PMF continues to improve over recent years. Important racial and gender variations exist, which were noted in our study.

Open article ↗



2026-08-28 | Management of polycythemia vera to reduce thrombotic events and mortality with phlebotomy and cytoreductive therapy in veterans affairs healthcare system.

Patients with polycythemia vera (PV) have increased incidence of thrombotic events (TEs) that contribute to higher mortality compared to age-matched controls. We aim to compare the impact of phlebotomy (PHL) and cytoreductive therapy (CT) on outcomes in US veterans with PV between Oct 2017 and Dec 2023. PV treatment was categorized into three groups: CT, PHL, and no documented treatment. Among 11,809 veterans with PV, 7151 (60.6%) received CT or PHL treatments. After excluding those with events before or within 90 days of index date (PV diagnosis), we identified 5287 and 5245 qualified patients to examine treatment impact on mortality and TE, respectively. The mortality rate was 15.4% (n = 816), with a median survival time of 4.5, 4.9 or 4.3 years for patients under CT, PHL only, or no treatment, respectively. The TE rate was 9.4% (n = 496), with a median duration (from index date to the first TE or censored date) of 4.2, 4.7, or 4.0 years for patients under CT, PHL, or no treatment, respectively. Both CT and PHL reduced mortality, and there was no significant difference between CT and PHL that lowered the risk of TE. Compared with patients with no documented treatment, patients treated with CT had a 43% lower risk of mortality (HR 0.57, 95% CI 0.45-0.75; p < 0.01), and patients treated with PHL had a 20% lower risk of mortality (HR 0.80, 95% CI 0.65-1.00; p = 0.05). Therefore, in patients with PV, treatment with CT had similar outcome on TE or mortality, compared to those treated with PHL.

Open article ↗



2026-08-11 | First Philippine report of myeloproliferative neoplasms with concurrent JAK2 and BCR::ABL1 mutations.

Myeloproliferative neoplasms (MPNs) are broadly classified into BCR::ABL1-positive chronic myeloid leukaemia (CML) and BCR::ABL1-negative subtypes such as polycythaemia vera (PV), essential thrombocythaemia and primary myelofibrosis. Although traditionally considered mutually exclusive, rare cases of coexisting BCR::ABL1 rearrangement and Janus kinase 2 (JAK2) mutation have increasingly been recognised.We report the first Philippine case series of three patients with concurrent CML and JAK2-positive MPNs. Two patients developed PV 6-9 years after the initial diagnosis of CML despite ongoing tyrosine kinase inhibitor (TKI) therapy and molecular response, while a third patient had persistent thrombocytosis and was later found to have a concomitant JAK2-mutated MPN with fibrotic marrow features after 4 years.Compared with previously reported cases, our series demonstrates similarly delayed emergence of JAK2-mutated clones while highlighting real-world challenges in TKI intolerance, sequential TKI use and the need for combined cytoreductive strategies in a resource-limited setting.

Open article ↗



cell therapies
2026-07-30 | Evaluation of the efficacy of erythrocytapheresis and phlebotomy in the treatment of polycythemia.

Systematic comparison of the efficacy and safety of erythrocytapheresis and phlebotomy. A retrospective analysis of 108 polycythemia patients categorized into four treatment groups: 1, 2, or 3 sessions of phlebotomy, and 1 session of erythrocytapheresis. The primary outcome was HGB change. One-way analysis of variance (ANOVA), Kruskal-Wallis H test, t-tests, and linear regression were used to compare efficacies and identify predictive factors, with subgroup analyses for polycythemia vera (PV) and high-altitude polycythemia (HAPC). Linear trend analysis was performed to evaluate the dose-response relationship.The references cited in this article were retrieved through the PUBMED database. A significant difference in HGB change was observed among four groups. 3 sessions of phlebotomy were superior to 1 and 2 sessions. 1 session of erythrocytapheresis achieved comparable HGB change to 2-3 phlebotomy sessions. Linear trend analysis confirmed HGB change increased with phlebotomy sessions. In the PV subgroup, baseline HGB and female gender were predictors of HGB change. In the HAPC subgroup, only baseline HGB was a significant predictor. 2-3 sessions of phlebotomy are non-inferior to 1 session of erythrocytapheresis in efficacy, with higher safety and cost-effectiveness, and baseline HGB is a universal predictor of therapeutic efficacy.

Open article ↗



2025-05-28 | CRISPR/Cas9-Based Modeling of JAK2 V617F Mutation in K562 Cells Reveals Enhanced Proliferation and Sensitivity to Therapeutic Agents.

The Janus kinase 2 (JAK2) protein fulfills an important role in hematopoiesis via the Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway, as it provides the genetic driver of BCR::ABL1-negative myeloproliferative neoplasms (MPNs), which are clinically manifested as polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). The most common cause of MPNs is the mutation of JAK2 V617F in the JAK2 gene, which results in increased cell proliferation. However, both the pathogenesis and treatment regimen of BCR::ABL1-negative MPNs remain poorly understood. The aim of the present study was to establish K562 cell lines with a point mutation in exon 14 (JAK2p.V617F) using CRISPR/Cas9 technology. The modified JAK2 V617F cell lines were examined for the gene mutation using droplet digital PCR (DDPCR), and the presence of the mutation was confirmed by DNA sequencing. Modified cells were characterized by measuring JAK2 gene expression and the extent of cell proliferation. Interferon α2a (IFN-α2a) and arsenic trioxide were also administered to the cells to explore their potential effects. The JAK2 V617F-mutated cells were found to exhibit a higher level of JAK2 gene expression compared with the wild type. Interestingly, a significant increase in the proliferation rate was observed with the modified cells compared with the wild type cells (p < 0.001), as assessed from the JAK2 gene expression levels. Furthermore, the treatments with IFN-α2a and arsenic trioxide led to the preferential suppression of the cell proliferation rate of the K562 expressing mutant JAK2 cells compared with the wild type cells, and this suppression occurred in a dose-dependent manner(p < 0.01). Moreover, the modified cells were able to differentiate into megakaryocyte-like cells following stimulation with phorbol 12 myristate 13 acetate (PMA). Taken together, the results of the present study have shown that the CRISPR/Cas9-modified JAK2 V617F model may be used as a disease model in the search of novel therapies for MPNs.

Open article ↗



2025-05-24 | Clinical application of erythrocytapheresis in the treatment of erythrocytosis.

This study aimed to clarify the clinical utility of erythrocytapheresis as a treatment for erythrocytosis, including polycythemia vera and secondary erythrocytosis. A retrospective analysis was conducted on 83 patients (84.34 % male, mean age 49.66 years (16.23 years)) who underwent a total of 104 erythrocytapheresis sessions between September 2021 and April 2025. The key parameters measured included the depleted red blood cell (RBC) volume, the hemoglobin (HB) and hematocrit (Hct) reductions, and adverse reactions. Erythrocytapheresis significantly reduced the post-treatment RBC counts (25.22 %), the HB (25.19 %) level and the Hct (23.62 %), the white blood cell counts, (23.37 %) and the platelet counts (8.38 %) (all p < 0.05). The median depleted RBC volume was 1405.5 mL (range 1011.75-1677.5 mL). The median post-treatment target Hct was 40 % (range 40-45 %). The mean post-treatment Hct was in fact 47.57 % (6.54 %), which was higher than the target, and the mean Hct error ratio was 14.23 % (12.95 %). When the replacement solution was physiological saline, an adverse reaction (hypotension) occurred during 4.81 % of the 104 erythrocytapheresis sessions, but only in patients with a depleted RBC volume/weight (D/W) ≥ 25 mL/kg. No significant differences were observed between the Spectra Optia and COM.TEC blood cell separators. Erythrocytapheresis effectively reduces the RBC mass in patients with erythrocytosis.In rough terms, the post-treatment target Hct = the post-treatment Hct × 0.88, our research team has officially designated this formula as the 'Southwest Formula'. In the future, we will continue to expand the sample size to enhance the precision of this formula and better guide the clinical application of erythrocytapheresis.

Open article ↗



2024-08-31 | Impact of Phlebotomy on Quality of Life in Low-Risk Polycythemia Vera.

Polycythemia vera is an indolent myeloproliferative disorder that predisposes patients to venous and arterial thrombosis and can transform into myelofibrosis and acute myeloid leukemia. Consistent phlebotomy prevents life-threatening cerebrovascular and coronary artery disease and prolongs survival in low-risk polycythemia vera (patients under 60 years without thrombosis). However, despite its effectiveness in preventing serious complications, phlebotomy does not necessarily enhance the quality of life (QoL). This review assesses QoL issues associated with low-risk PV, explores alternative management strategies such as erythrocytapheresis, and discusses the roles of hydroxyurea, peginterferon, ruxolitinib, and other novel agents in potentially improving disease management and patient outcomes.

Open article ↗



2024-06-17 | A comparison between erythrocytapheresis and venesection for the treatment of JAK2-mutated polycythaemia.

JAK2-mutated polycythaemia vera (PV) is associated with reduced survival because of thrombotic events and haematological disease transformation. Therapeutic venesection has traditionally been used to lower haematocrit, but the technique of erythrocytapheresis has emerged over the last decade. To compare erythrocytapheresis with venesection as treatment for PV by assessing medical efficacy and financial viability. One hundred sixteen patients with PV who received red cell depletion therapy at Barwon Health between 2014 and 2021 were identified. The haematocrit drop after each session, interval between treatment times and number of sessions required to achieve a haematocrit <0.45 were compared with an independent t test. Thrombosis rates were compared with Pearson's chi-squared test. Cost-funding analysis was done by assessing the Weighted Inlier Equivalent Separation and National Weighted Activity Unit funding models. Patients treated with erythrocytapheresis achieved a greater haematocrit drop each treatment session (0.075 vs 0.03, P < 0.01), required fewer sessions to achieve a haematocrit <0.45 (1 vs 4, P < 0.01) and experienced fewer thrombotic complications (8.7% vs 32.1%, P = 0.02) than those treated with venesection. Cost-funding analysis demonstrated that erythrocytapheresis was more financially viable with a surplus of AU$297 per session compared to a deficit of AU$176 with venesection. Even if funding for venesection is increased, the cost of erythrocytapheresis may be mitigated by a lower number of procedures required per year (3.8 vs 5.3, P < 0.01). Erythrocytapheresis is more efficacious than venesection for the treatment of PV and is accompanied by rapid reductions in haematocrit and reduced thrombotic complications.

Open article ↗



proteins
2026-08-28 | Targeting the hepcidin-ferroportin axis in polycythemia vera: a complementary approach to clone-directed therapies.

Polycythemia vera (PV) is a clonal myeloproliferative neoplasm in which erythrocytosis, although driven by constitutive JAK2 signaling, remains dependent on iron availability. This dependency provides a rationale for therapeutic targeting of the hepcidin-ferroportin axis, whose modulation induces functional iron restriction and constrains erythropoiesis. The hepcidin mimetic rusfertide has shown durable hematocrit control and marked reduction of phlebotomy requirements across phase 2 and phase 3 studies, with predictable changes in systemic iron markers. However, current evidence is largely based on surrogate hematologic endpoints, and whether iron-directed strategies reduce thrombotic risk or modify disease trajectory remains undefined. Within this framework, iron metabolism can be viewed as a downstream, regulatable determinant of erythropoietic output, distinct from but integrated with clonal and inflammatory signaling. This review summarizes biological and clinical evidence on iron homeostasis in PV, focusing on the hepcidin-ferroportin axis and its integration with clone-directed therapies.

Open article ↗



2026-08-07 | Ropeginterferon alfa-2b in Polycythemia Vera: A systematic review and meta-analysis.

Ropeginterferon alfa-2b, a novel monopegylated interferon with improved pharmacokinetics, has emerged as a promising cytoreductive agent for managing polycythemia vera (PV). Despite increasing adoption, evidence synthesis of its efficacy and safety compared to standard care remains limited. The manuscript aimed to evaluate the efficacy of ropeginterferon alfa-2b in comparison to standard treatment options, including hydroxyurea and phlebotomy, in achieving complete hematologic response, partial molecular response (PMR), and reducing JAK2V617F allele burden in patients with PV. A systematic search of 4 databases was conducted up to April 2025, following PRISMA 2020 guidelines. Randomized controlled trials (RCTs) comparing ropeginterferon alfa-2b with standard therapies in PV patients were included. Meta-analyses were performed using random-effects models to derive odds ratios for dichotomous outcomes and mean differences (MDs) for continuous outcomes. Sensitivity and subgroup analyses were conducted, and risk of bias was assessed using RoB 2.0. Three RCTs comprising 522 patients were analyzed. Ropeginterferon alfa-2b showed no statistically significant advantage overall or over hydroxyurea for complete hematological response (CHR), PMR, or JAK2 allele burden reduction. However, subgroup analyses revealed significant benefits over phlebotomy alone in all 3 outcomes: CHR (odds ratio [OR] 3.05; 95% confidence interval [CI]: 1.36-6.80; P = .007), PMR (OR 36.34; 95% CI: 2.11-625.93; P = .01), and allele burden reduction (MD -13.70; 95% CI: -19.24 to -8.16; P < .00001). Ropeginterferon alfa-2b demonstrates no statistically significant difference compared to hydroxyurea, but gives better outcomes over phlebotomy in short-term efficacy for PV management. Its favorable molecular and hematologic outcomes support its role as a disease-modifying therapy, particularly in low-risk patients. However, larger and longer-term trials are needed to confirm these benefits across broader populations.

Open article ↗



2026-07-16 | Successful Topical Treatment of Hydroxyurea-Induced Ulcers Without Drug Discontinuation: A Case Report.

Hydroxyurea, an antineoplastic agent, is widely used to treat essential thrombocythemia and polycythemia vera. Although hydroxyurea-induced skin ulcers are uncommon, they are a recognized long-term adverse effect. Current management generally recommends discontinuation of hydroxyurea as the mainstay of treatment; however, drug withdrawal may aggravate the underlying hematologic disease. We report a case of bilateral medial malleolar ulcers associated with hydroxyurea therapy in a 65-year-old man with essential thrombocythemia, who showed marked improvement after two months of topical treatment with recombinant bovine basic fibroblast growth factor (rb-bFGF) gel, without discontinuation of hydroxyurea. Complete healing was confirmed at 25-month follow-up, while hematologic disease control was maintained. This case suggests that localized wound care with topical rb-bFGF may represent a feasible therapeutic option in selected patients when hydroxyurea discontinuation is not feasible.

Open article ↗



2026-05-03 | Hematologic and molecular response to ropeginterferon alfa-2b in patients with polycythemia vera: a systematic review and meta-analysis.

Ropeginterferon alfa-2b is an interferon used in the treatment of myeloproliferative neoplasms, particularly polycythemia vera. Its efficacy in achieving hematologic and molecular responses has been demonstrated in clinical trials, but pooled data on long-term outcomes and sustained response remain limited. This systematic review and meta-analysis aimed to evaluate the hematologic and molecular response over 36 months. PubMed, Scopus, Science Direct, and Google Scholar databases were searched to identify studies reporting hematologic and molecular responses to ropeginterferon alfa-2b. Studies were included if they provided data on complete hematologic response (CHR) and JAK2V617F variant allele frequency (VAF) reduction. Pooled proportions and mean reductions were calculated using random-effects models. The pooled proportion of CHR increased progressively from 0.19 (95% CI: 0.04-0.57) at 3 months to 0.73 (95% CI: 0.17-0.97) at 36 months. Molecular response, measured by VAF reduction, deepened over time from - 7.33 (95% CI: -9.85 to -4.81) at 3 months to -54.90 (95% CI: -65.61 to -43.99) at 36 months. Subgroup analyses revealed significant variability in response rates, particularly in early follow-up periods. Ropeginterferon alfa-2b achieves significant and sustained hematologic and molecular responses over 36 months. This makes it a promising treatment for polycythemia vera. While variability in early responses needs further investigation, the sustained long-term efficacy compared to hydroxyurea supports its use in clinical practice. Future studies should focus on identifying predictors of response and optimizing treatment protocols to maximize patient outcomes.

Open article ↗



2026-04-11 | Ropeginterferon dose-escalation strategies in polycythemia vera: a systematic review and meta-analysis

Abstract Background Ropeginterferon alfa-2b is increasingly used as a long-acting interferon therapy for polycythemia vera (PV), providing hematologic and molecular benefits. However, clinical studies have implemented different dose-escalation strategies, and their impact on outcomes has not been systematically evaluated. Methods A systematic search of PubMed, Embase, and the Cochrane Library (September 24, 2025) identified studies reporting clinical outcomes of ropeginterferon in PV. Nine studies met eligibility criteria. Two reviewers independently extracted data, and meta-analyses were conducted using random-effects models. Subgroup analyses compared slow dose-up (SDU) and rapid dose-up (RDU) regimens at 1-, 2-, and 3-year follow-up when available. Results The pooled 1-year complete hematologic response (CHR) rate was 0.59 (95% CI, 0.47–0.71). RDU regimens yielded significantly higher CHR than SDU at both 1 year (0.67 vs. 0.41; p < 0.001) and 2 years (0.75 vs. 0.63; p = 0.038). Molecular response (MR) also favored RDU at 1 year (0.59 vs. 0.36; p < 0.001), with differences diminishing at 2 years. The pooled 1-year reduction in JAK2 V617F allele burden was − 22.2% (95% CI, − 34.2% to − 10.2%; p < 0.001). Safety outcomes were favorable, with low rates of thrombosis (4%), serious adverse events (5%), and treatment discontinuation (7%). Conclusions Ropeginterferon alfa-2b provides meaningful hematologic and molecular responses with an acceptable safety profile in PV. Rapid dose-escalation facilitates earlier CHR and MR without increasing toxicity, suggesting titration speed as an important determinant of early treatment optimization.

Open article ↗



antibodies
2026-08-19 | Myeloproliferative Neoplasms.

Classic myeloproliferative neoplasms, including essential thrombocythemia, polycythemia vera, and primary myelofibrosis, are chronic, clonal hematopoietic stem-cell disorders. These disorders are driven by gain-of-function mutations in the genes Janus kinase 2 (JAK2), calreticulin (CALR), or the thrombopoietin receptor (MPL) that activate cytokine signaling. These mutations arise decades before clinical disease develops and confer a clonal advantage that is further shaped by comutations in epigenetic, splicing, or signaling genes. Inflammation enhances clonal dominance, favoring the development of myelofibrosis and thrombotic complications. Disease evolution may culminate in secondary acute myeloid leukemia, which has a poor prognosis. Current therapies primarily aim to control symptoms, thrombosis, and splenomegaly, but they have limited disease-modifying effects, except for pegylated interferon alfa and JAK2 inhibitors in some patients. Emerging therapies that selectively target mutant CALR and JAK2 V617F using immunotherapy and selective inhibitors could be a breakthrough in the treatment of persons with myeloproliferative neoplasms, with the expectation of achieving durable disease modification and potentially clonal eradication.

Open article ↗



2026-04-29 | A Phase 1 Randomized, Double-Blind, Placebo-Controlled Single and Multiple Ascending Dose Study of DISC-3405, a Novel Recombinant Humanized Monoclonal Antibody Targeting TMPRSS6, in Adult Healthy Volunteers.

Hepcidin is the central regulator of iron homeostasis, controlling iron sequestration and dietary iron absorption. Transmembrane serine protease 6 (TMPRSS6) suppresses hepcidin via the bone morphogenetic protein/small mothers against decapentaplegic (BMP/SMAD) pathway by cleaving the co-receptor hemojuvelin. DISC-3405 is a novel humanized monoclonal antibody that enhances hepcidin expression by inhibiting TMPRSS6, thereby promoting iron restriction. This Phase 1 study evaluated the safety/tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of DISC-3405 or placebo in 56 healthy participants. DISC-3405 (37.5 to 300 mg) or placebo was administered subcutaneously (SC) or intravenously (IV). DISC-3405 was well tolerated. No deaths, serious adverse events, or participant discontinuations occurred. Most treatment-emergent adverse events were Grade 1 (mild) in severity, with 2 participants reporting Grade 2 (moderate) events following single dosing and no Grade 3/4 (severe/life-threatening) events reported. Median time to maximum plasma concentration was ≈96 to 168 h. Elimination half-life rose from 130 h at 37.5 mg to 265 h at 300 mg, with a clinically relevant half-life of ≈11 days. Absolute bioavailability was 39.7% (75 mg SC vs. IV). Minor accumulation occurred with repeat 4-week dosing of two doses, and PK was greater than dose proportional. DISC-3405 increased hepcidin-25 and reduced serum iron and transferrin saturation across dose levels. Single and repeated dosing of DISC-3405 produced reductions in reticulocyte hemoglobin, hemoglobin, and hematocrit. Overall, DISC-3405 was well tolerated with PK/PD data supporting further development for patients who could benefit from iron restriction, such as those with polycythemia vera.

Open article ↗



2025-11-30 | Mesenchymal stromal cells secretory pattern contributes to oncoinflammatory bone marrow microenvironment in polycythemia vera.

Polycythemia vera is a myeloproliferative neoplasm marked by an increased proliferation of erythroid mature and precursors cells in bone marrow and peripheral blood. The pathophysiology is linked to the presence of the JAK2 driver mutation, epigenetic deregulation, and alterations in the bone marrow hematopoietic niche. Multipotent mesenchymal stromal cells (MSC) in the bone marrow, which are crucial for maintenance and development of hematopoietic stem cells, play a role in the communication between neoplastic cells and resident bone marrow cells by releasing various mediators that either suppress or promote tumor progression. These mediators include several essential immunomodulatory molecules, pro-angiogenic and growth factors. We hypothesized that MSC from polycythemia vera patients (Patient Group) would exhibit distinct properties compared to those from healthy donors (Control Group), thereby influencing the hematopoietic niche and contributing to disease pathogenesis. This study characterized MSC from patients, focusing on their secretory, proteomic, and phenotypic properties. MSC from the Patient and Control Groups had similar immunophenotypes and multipotentiality. However, MSC from the Patient Group exhibited reduced immunomodulatory properties, and released distinct soluble immune and angiogenic mediators when compared with the Control Group. Global proteomic analysis revealed that MSC from patients presented upregulated expressions of FAM175B, VP526A, CTTN, MAP4, BAX, and TPD52L2 but a downregulated TNC expression. These results indicate that MSC contribute to the inflammation pattern in the hematopoietic niche. The secretory and proteomic profile of MSC from patients, indicate that these cells may influence immune cell function, induce neoangiogenesis, and alter cell-to-cell interactions within the bone marrow, thereby fostering a pro-tumor microenvironment and favoring disease pathogenesis. These findings highlight the potential of targeting MSC-mediated pathways as a therapeutic strategy in polycythemia vera.

Open article ↗



2025-10-27 | Unveiling CD177: a key player in tumors, autoimmune diseases, and inflammatory disorders.

CD177, also referred to as human neutrophil antigen NB1 or polycythemia rubra vera-1, is a glycosylphosphatidylinositol-anchored glycoprotein with a molecular weight of approximately 58-64 kDa, predominantly expressed in neutrophils, neutrophilic myelocytes, and metamyelocytes. While extensive research has focused on the role of CD177 in neutrophils, where it is implicated in transendothelial migration, cellular viability, and bactericidal activities, its functions outside of neutrophils remain largely unexplored. Under inflammatory conditions, CD177 expression on neutrophils is significantly upregulated, facilitating their migration to sites of inflammation. CD177+ neutrophils have been shown to accumulate in inflamed tissues and modulate the release of inflammatory mediators and the formation of neutrophil extracellular traps (NETs), correlating with the severity of inflammation in conditions such as inflammatory bowel disease (IBD) and acute respiratory distress syndrome (ARDS). An imbalance in CD177+ neutrophils has been identified as a critical pathogenic mechanism in vascular inflammation, tissue necrosis, and systemic lupus erythematosus (SLE). Furthermore, CD177 expression on neutrophils, epithelial cells, and regulatory T cells in solid tumors has been associated with tumor invasion, disease stage, therapeutic responses, and patient survival in various cancers, including gastric, breast, and colorectal cancer (CRC). Nevertheless, elucidating the intricate mechanisms underlying CD177's role in these diseases remains a significant challenge. In light of these findings, we present a comprehensive review of recent literature concerning the role of CD177 in tumors, inflammatory processes, and autoimmune diseases, with a particular focus on its mediating effects on neutrophil recruitment, transepithelial migration, and the activation of CD177-positive neutrophils, along with the functional implications of CD177 expression beyond neutrophils. A deeper understanding of CD177 may pave the way for the development of novel therapeutic strategies and the assessment of disease prognosis.

Open article ↗



2024-12-10 | JAK2 mutations in polycythemia vera: from molecular origins to inflammatory pathways and clinical implications

Summary Polycythemia vera (PV) is a myeloproliferative neoplasm primarily driven by mutations in the JAK2 gene, most notably the V617F mutation, which occurs in nearly 97% of cases. This gain-of-function mutation overactivates the JAK-STAT pathway, a critical factor in developing the PV phenotype by stimulating excessive proliferation of the erythroblastic lineage. Diagnostic methods for PV focus on detecting the JAK2 mutation—primarily through polymerase chain reaction (PCR) and next-generation sequencing, which are essential for distinguishing PV from other disorders. The variant allele frequency (VAF) of JAK2 V617F also serves as an important prognostic marker, with higher VAF linked to both increased thrombotic risk and disease progression to myelofibrosis or acute leukemia. Thus, managing allele burden is central to treatment strategies. Given the genetic complexity of PV, personalized treatment approaches are essential. Current therapies focus on JAK2 signaling, with ropeginterferon alfa-2b and JAK inhibitors as primary or secondary treatments to reduce clonal expansion and control inflammation, and aspirin to prevent thrombotic events. Emerging treatments are exploring anti-inflammatory strategies, such as anti-IL-1β antibodies, and agents targeting iron metabolism to maintain hematocrit levels without phlebotomy, potentially improving quality of life. Overall, reducing JAK2 V617F burden and controlling inflammation are crucial for managing PV progression and improving patient outcomes, with ongoing research refining these therapeutic avenues to enhance long-term strategies.

Open article ↗



other
2026-08-18 | Sapablursen for Erythrocytosis Control in Patients with Polycythemia Vera.

Polycythemia vera is characterized by erythrocytosis and increased risk of thrombosis. Sapablursen is an antisense oligonucleotide that suppresses transmembrane serine protease 6 (TMPRSS6), increases hepcidin production, and reduces iron availability for erythropoiesis. IMPRSSION; an ongoing phase 2a, randomized, open-label study includes patients meeting 2016 WHO criteria for polycythemia vera, requiring ≥3 phlebotomies within 6 months of screening and ≥1 phlebotomy within the last 12 weeks. Cohort A (120 or 80 mg) and Cohort B (40 mg) received sapablursen subcutaneously once every 4 weeks (Q4W). The primary efficacy endpoint was the reduction in phlebotomy frequency from baseline to weeks 17-37 in patients who received ≥1 dose. Forty-nine patients received ≥1 sapablursen dose (median age 61 years; 82% male). The baseline mean±SD weekly phlebotomy rate was 0.15±0.07 in Cohort A; 0.17±0.07 in Cohort B and was reduced by -0.10 (95%CI, -0.13, -0.07; n=32;p<0.0001) in Cohort A; -0.10 (95%CI, -0.14, -0.06; n=17;p=0.0001) in Cohort B. Sapablursen reduced the median (IQR) number of phlebotomies from 5.0 (3.0-6.0,Cohort A; 3.5-6.5,Cohort B) at baseline (26-weeks) to 0 (0-1.0) in the efficacy evaluation window (20-weeks) in Cohort A and 1.5 (0-2.5) in Cohort B. Most adverse events were mild or moderate; anemia and fatigue were most common. The mean change in MPN-SAF-TSS at week 37 was -6.21 points (95%CI: -10.56, -1.85, p=0.0052) in Cohort A; -2.71 points in Cohort B (95% CI: -8.33, 2.91, p=0.34). Sapablursen reduced phlebotomy need, improved symptoms, and was safe and well-tolerated in patients with polycythemia vera. (Funded by Ionis Pharmaceuticals; ClinicalTrials.gov: NCT05143957).

Open article ↗



2026-07-31 | A Therapeutic Dilemma: Catastrophic ST-Elevation Myocardial Infarction Following Antiplatelet Therapy Interruption in a Patient With JAK2-Positive Polycythemia Vera.

Polycythemia vera is associated with a thrombotic-hemorrhagic paradox. We report a 75-year-old woman with recurrent ST-elevation myocardial infarction and stent thrombosis after premature dual antiplatelet therapy interruption. Revascularization was successful, and eptifibatide bridging enabled safe surgery. This case highlights the risks of interruption and the role of bridging therapy.

Open article ↗



2025-12-02 | Recent advancements in aptamer-mediated theranostics in the management of hematological disorders.

Increasing trends in the incidence rate and death rate in hematological disorders, specifically hematological malignancies, indicate the need for advancements in therapeutic approaches. Various hematological disorders include hemophilia, leukemia, lymphoma, myeloma, thrombocytopenia, sickle cell anemia, thalassemia, polycythemia vera, and aplastic anemia. Chemotherapy, cytoreductive therapy, and monoclonal antibodies are typically used for the treatment of hematological disorders. Stem cell transplantation is also performed for this purpose. However, these conventional therapeutic approaches exhibit several drawbacks, such as nonspecificity and side effects. Aptamers, being RNA or DNA oligonucleotides, selectively bind to a specific complementary molecule and serve as strong therapeutic components, offering significant theranostic implications and numerous therapeutic and diagnostic alternatives for hematological disorders. This article explains the systematic evolution of ligands through exponential enrichment, also known as the SELEX process of aptamer selection, their mechanism of action, and their wide range of applications. Moreover, it discusses the various advanced approaches for aptamer modifications to enhance their flexibility, expanding their applicability. This review article focuses on the recent updates in the application of aptamers in different hematological disorders, highlighting their potential in the therapy and diagnosis of hematological diseases.

Open article ↗



2025-11-03 | Evaluation of the novel TMPRSS6 antisense inhibitor sapablursen for treatment of polycythemia vera: Results of the imprssion clinical trial

Abstract Background: Polycythemia vera (PV) is characterized by excessive erythrocytosis and elevated hematocrit (Hct), which is associated with increased risk of thrombotic events. Controlling Hct levels (&lt;45%) is a key therapeutic goal to reduce thrombotic events. Sapablursen (ISIS 702843) is a liver-directed, ligand-conjugated antisense oligonucleotide that suppresses transmembrane serine protease 6 (TMPRSS6) to enhance hepcidin production thereby restricting iron availability and reduced erythrocytosis. We are reporting the topline results of the IMPRSSION study (NCT05143957), an ongoing global, open-label phase 2 trial evaluating the safety and efficacy of sapablursen for Hct control and reducing phlebotomy rate in patients with PV. Methods: Eligible patients met 2016 WHO diagnostic criteria for PV, were required to have &gt;3 phlebotomies within six months prior to screening, including &gt;1 phlebotomy in the last 12 weeks. There were no exclusions for HCT prior to randomization. Patients received monthly subcutaneous doses of sapablursen in Cohort A (high dose) or Cohort B (low dose), during a 37-week treatment period. The primary efficacy endpoint was the reduction in the frequency of phlebotomy during the last 20 weeks of the treatment period (Week 17-37) compared to baseline (defined as the mean weekly phlebotomy rate during the six months prior to screening through the first dose of sapablursen). Phlebotomy was performed when Hct levels were ≥45% or at the investigator's discretion, confirmation of Hct was not required for phlebotomy. Serial assessments of serum hepcidin, TSAT and ferritin were conducted. The 10-item Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (MPN-SAF-TSS) assessed the change in symptoms from baseline to Week 37. Results: Forty-nine (49) patients received at least one dose of sapablursen (full analysis set) in either Cohort A (n=32) or Cohort B (n=17). The median age was 61 years, 40 (82%) were male, and 29 (59%) classified as high risk. The primary endpoint was met at both dose levels. The weekly phlebotomy rate (mean±SD) decreased from baseline of 0.15±0.07 (~7.8/yr) to 0.05±0.09 (~2.6/yr) during the primary endpoint window (Week 17-37) in Cohort A (n=32, p&lt;0.0001; 95%CI, -0.13, -0.07), and from 0.17±0.07 (~8.9/yr) to 0.07±0.07 (~3.6/yr) in Cohort B (n=17, p=0.0001; 95%CI, -0.14, -0.06). The mean MPN-SAF-TSS was reduced at Week 37 by 32% in Cohort A (change from baseline LSM -6.2, p=0.005) and 11% in Cohort B (change from baseline LSM -2.7, p=0.344). The proportion of patients with Hct control (&lt;45%) without phlebotomy from week 17 to 37 in Cohort A and B was 53% (17/32) and 35% (6/17), respectively. Serum hepcidin was increased from baseline values of 0.25±0.6 to 5.05±4.7 nM at Week 13 in Cohort A (p&lt;0.0001) and from 0.68±1.7 to 2.06±3.6 nM in Cohort B (p=0.0142). A sustained low TSAT was observed between Weeks 17-37 (6.0±2.1% and 5.5±2.0% in Cohort A and 8.9±5.0% and 7.0±3.4% in Cohort B). Serum ferritin increased over time from 18±22 ng/mL and 28±58 ng/mL at baseline in Cohort A and B, respectively, to 44±47 ng/mL and 41±85 ng/mL at Week 37, respectively. Sapablursen was generally safe and well-tolerated. The incidence of injection site reactions was 12.2% (6/49). Injection site reactions did not recur following multiple injections, were not progressive and resolved spontaneously. There was one death on study due to transformation to AML which was deemed as not related to the study drug. Conclusions: Treatment of PV patients with sapablursen increased serum hepcidin, controlled Hct, reduced phlebotomy need and improved quality of life in a dose-dependent manner. These findings highlight the potential of sapablursen as a therapeutic approach in PV and support further development.

Open article ↗



2024-01-22 | Idiopathic erythrocytosis: a germline disease?

Polycythemia Vera (PV) is typically caused by V617F or exon 12 JAK2 mutations. Little is known about Polycythemia cases where no JAK2 variants can be detected, and no other causes identified. This condition is defined as idiopathic erythrocytosis (IE). We evaluated clinical-laboratory parameters of a cohort of 56 IE patients and we determined their molecular profile at diagnosis with paired blood/buccal-DNA exome-sequencing coupled with a high-depth targeted OncoPanel to identify a possible underling germline or somatic cause. We demonstrated that most of our cohort (40/56: 71.4%) showed no evidence of clonal hematopoiesis, suggesting that IE is, in large part, a germline disorder. We identified 20 low mutation burden somatic variants (Variant allelic fraction, VAF, < 10%) in only 14 (25%) patients, principally involving DNMT3A and TET2. Only 2 patients presented high mutation burden somatic variants, involving DNMT3A, TET2, ASXL1 and WT1. We identified recurrent germline variants in 42 (75%) patients occurring mainly in JAK/STAT, Hypoxia and Iron metabolism pathways, among them: JAK3-V722I and HIF1A-P582S; a high fraction of patients (48.2%) resulted also mutated in homeostatic iron regulatory gene HFE-H63D or C282Y. By generating cellular models, we showed that JAK3-V722I causes activation of the JAK-STAT5 axis and upregulation of EPAS1/HIF2A, while HIF1A-P582S causes suppression of hepcidin mRNA synthesis, suggesting a major role for these variants in the onset of IE.

Open article ↗



small molecules
2026-09-30 | Masked polycythaemia vera presenting with extensive splanchnic venous thrombosis and mesenteric ischaemia.

Splanchnic venous thrombosis (SVT) is a potentially catastrophic manifestation of polycythaemia vera (PV). We report a woman in her 60s with masked PV who had been managed for 5 years with intermittent phlebotomy and aspirin without haematology referral, molecular testing or cytoreductive therapy. Chronic iron deficiency masked erythrocytosis, delaying diagnosis. She presented with extensive thrombosis involving the portal, splenic and superior mesenteric veins complicated by mesenteric ischaemia requiring exploratory laparotomy, jejunal resection and ileostomy. Bone marrow biopsy and JAK2 V617F testing confirmed PV. Therapeutic anticoagulation was initiated with enoxaparin and subsequently transitioned to apixaban, while hydroxyurea achieved sustained haematologic control. Interval imaging demonstrated thrombus regression with persistent cavernous transformation. Given ongoing portal hypertension, oesophageal varices, occasional mild ostomy bleeding and low body weight, anticoagulation was continued indefinitely at reduced intensity with apixaban 2.5 mg twice daily. At 21-month follow-up, the patient remained free of recurrent thrombosis and major bleeding.

Open article ↗



2026-09-01 | Diagnosis and Management of Polycythemia Vera Complicated by Cerebral Infarction and Subdural Hematoma: A Case Report

ABSTRACT Myeloproliferative neoplasms are hematologic disorders associated with increased thrombotic and hemorrhagic risk. However, they are often underrecognized in patients presenting with cerebrovascular events. We report the case of a 70‐year‐old man who developed an acute cerebral infarction in the left temporal lobe accompanied by limb weakness. Neuroimaging revealed multiple cerebrovascular stenoses and widespread atherosclerotic vascular disease. During follow‐up, he developed a subdural hematoma. Further evaluation demonstrated persistent blood count abnormalities and splenomegaly. Bone marrow biopsy revealed a hypercellular marrow with trilineage proliferation (panmyelosis), characterized by prominent erythroid, granulocytic, and megakaryocytic lineages. Molecular testing revealed the Janus kinase 2 Valine 617 Phenylalanine mutation. Combined with elevated hemoglobin levels, these findings fulfilled the diagnostic criteria for polycythemia vera in the fifth edition of the World Health Organization Classification of Haematolymphoid Tumors. This case highlights that coexisting ischemic and hemorrhagic cerebrovascular events with unexplained hematologic abnormalities or splenomegaly should prompt Janus kinase 2 mutation screening and bone marrow examination to enable early diagnosis of myeloproliferative neoplasm and prevent further complications.

Open article ↗



2026-09-01 | Incidence, prevalence, and survival outcomes of patients with myeloproliferative neoplasms in the United States: a Surveillance, Epidemiology, and End Results (SEER) database analysis, years 2000-2021.

Myeloproliferative Neoplasms (MPNs) are rare hematologic neoplasms. The epidemiology and outcomes of these rare neoplasms warrant an update considering new diagnostic tools and advances in treatment options. NCI's Surveillance, Epidemiology and End Results (SEER)-17 registries were interrogated to analyze adult patients diagnosed with MPN [ICD-O-3 codes: polycythemia vera (PV) 9950/3, essential thrombocythemia (ET) 9962/3, primary myelofibrosis (PMF) 9961/3 and chronic myeloid leukemia (CML) 9875/3] during the years 2000 to 2021. Data of 63,242 (ET, n = 24,172; PV, n = 23,456; PMF, n = 6131; CML, n = 9483) patients were analyzed. The overall incidence rate (IR) for ET, PV, PMF and CML was 1.8, 1.7, 0.5 and 0.7 per 100,000 person-years, respectively. The incidence of ET, PV, and MF increased with age, and the majority of cases were seen after the age of 50. 5-year Relative Survival (RS) for PMF was 50.9% in 2009, to 57.4% in 2013 and 60.6% in 2016. The median overall survival (OS) was 152 months for ET, 150 months for PV, 48 months for PMF, and 202 months for CML. Advancing age was associated with adverse survival across MPN subtypes. Survival of patients with PMF continues to improve over recent years. Important racial and gender variations exist, which were noted in our study.

Open article ↗



2026-08-28 | Management of polycythemia vera to reduce thrombotic events and mortality with phlebotomy and cytoreductive therapy in veterans affairs healthcare system.

Patients with polycythemia vera (PV) have increased incidence of thrombotic events (TEs) that contribute to higher mortality compared to age-matched controls. We aim to compare the impact of phlebotomy (PHL) and cytoreductive therapy (CT) on outcomes in US veterans with PV between Oct 2017 and Dec 2023. PV treatment was categorized into three groups: CT, PHL, and no documented treatment. Among 11,809 veterans with PV, 7151 (60.6%) received CT or PHL treatments. After excluding those with events before or within 90 days of index date (PV diagnosis), we identified 5287 and 5245 qualified patients to examine treatment impact on mortality and TE, respectively. The mortality rate was 15.4% (n = 816), with a median survival time of 4.5, 4.9 or 4.3 years for patients under CT, PHL only, or no treatment, respectively. The TE rate was 9.4% (n = 496), with a median duration (from index date to the first TE or censored date) of 4.2, 4.7, or 4.0 years for patients under CT, PHL, or no treatment, respectively. Both CT and PHL reduced mortality, and there was no significant difference between CT and PHL that lowered the risk of TE. Compared with patients with no documented treatment, patients treated with CT had a 43% lower risk of mortality (HR 0.57, 95% CI 0.45-0.75; p < 0.01), and patients treated with PHL had a 20% lower risk of mortality (HR 0.80, 95% CI 0.65-1.00; p = 0.05). Therefore, in patients with PV, treatment with CT had similar outcome on TE or mortality, compared to those treated with PHL.

Open article ↗



2026-08-11 | First Philippine report of myeloproliferative neoplasms with concurrent JAK2 and BCR::ABL1 mutations.

Myeloproliferative neoplasms (MPNs) are broadly classified into BCR::ABL1-positive chronic myeloid leukaemia (CML) and BCR::ABL1-negative subtypes such as polycythaemia vera (PV), essential thrombocythaemia and primary myelofibrosis. Although traditionally considered mutually exclusive, rare cases of coexisting BCR::ABL1 rearrangement and Janus kinase 2 (JAK2) mutation have increasingly been recognised.We report the first Philippine case series of three patients with concurrent CML and JAK2-positive MPNs. Two patients developed PV 6-9 years after the initial diagnosis of CML despite ongoing tyrosine kinase inhibitor (TKI) therapy and molecular response, while a third patient had persistent thrombocytosis and was later found to have a concomitant JAK2-mutated MPN with fibrotic marrow features after 4 years.Compared with previously reported cases, our series demonstrates similarly delayed emergence of JAK2-mutated clones while highlighting real-world challenges in TKI intolerance, sequential TKI use and the need for combined cytoreductive strategies in a resource-limited setting.

Open article ↗



cell therapies
2026-07-30 | Evaluation of the efficacy of erythrocytapheresis and phlebotomy in the treatment of polycythemia.

Systematic comparison of the efficacy and safety of erythrocytapheresis and phlebotomy. A retrospective analysis of 108 polycythemia patients categorized into four treatment groups: 1, 2, or 3 sessions of phlebotomy, and 1 session of erythrocytapheresis. The primary outcome was HGB change. One-way analysis of variance (ANOVA), Kruskal-Wallis H test, t-tests, and linear regression were used to compare efficacies and identify predictive factors, with subgroup analyses for polycythemia vera (PV) and high-altitude polycythemia (HAPC). Linear trend analysis was performed to evaluate the dose-response relationship.The references cited in this article were retrieved through the PUBMED database. A significant difference in HGB change was observed among four groups. 3 sessions of phlebotomy were superior to 1 and 2 sessions. 1 session of erythrocytapheresis achieved comparable HGB change to 2-3 phlebotomy sessions. Linear trend analysis confirmed HGB change increased with phlebotomy sessions. In the PV subgroup, baseline HGB and female gender were predictors of HGB change. In the HAPC subgroup, only baseline HGB was a significant predictor. 2-3 sessions of phlebotomy are non-inferior to 1 session of erythrocytapheresis in efficacy, with higher safety and cost-effectiveness, and baseline HGB is a universal predictor of therapeutic efficacy.

Open article ↗



2025-05-28 | CRISPR/Cas9-Based Modeling of JAK2 V617F Mutation in K562 Cells Reveals Enhanced Proliferation and Sensitivity to Therapeutic Agents.

The Janus kinase 2 (JAK2) protein fulfills an important role in hematopoiesis via the Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway, as it provides the genetic driver of BCR::ABL1-negative myeloproliferative neoplasms (MPNs), which are clinically manifested as polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). The most common cause of MPNs is the mutation of JAK2 V617F in the JAK2 gene, which results in increased cell proliferation. However, both the pathogenesis and treatment regimen of BCR::ABL1-negative MPNs remain poorly understood. The aim of the present study was to establish K562 cell lines with a point mutation in exon 14 (JAK2p.V617F) using CRISPR/Cas9 technology. The modified JAK2 V617F cell lines were examined for the gene mutation using droplet digital PCR (DDPCR), and the presence of the mutation was confirmed by DNA sequencing. Modified cells were characterized by measuring JAK2 gene expression and the extent of cell proliferation. Interferon α2a (IFN-α2a) and arsenic trioxide were also administered to the cells to explore their potential effects. The JAK2 V617F-mutated cells were found to exhibit a higher level of JAK2 gene expression compared with the wild type. Interestingly, a significant increase in the proliferation rate was observed with the modified cells compared with the wild type cells (p < 0.001), as assessed from the JAK2 gene expression levels. Furthermore, the treatments with IFN-α2a and arsenic trioxide led to the preferential suppression of the cell proliferation rate of the K562 expressing mutant JAK2 cells compared with the wild type cells, and this suppression occurred in a dose-dependent manner(p < 0.01). Moreover, the modified cells were able to differentiate into megakaryocyte-like cells following stimulation with phorbol 12 myristate 13 acetate (PMA). Taken together, the results of the present study have shown that the CRISPR/Cas9-modified JAK2 V617F model may be used as a disease model in the search of novel therapies for MPNs.

Open article ↗



2025-05-24 | Clinical application of erythrocytapheresis in the treatment of erythrocytosis.

This study aimed to clarify the clinical utility of erythrocytapheresis as a treatment for erythrocytosis, including polycythemia vera and secondary erythrocytosis. A retrospective analysis was conducted on 83 patients (84.34 % male, mean age 49.66 years (16.23 years)) who underwent a total of 104 erythrocytapheresis sessions between September 2021 and April 2025. The key parameters measured included the depleted red blood cell (RBC) volume, the hemoglobin (HB) and hematocrit (Hct) reductions, and adverse reactions. Erythrocytapheresis significantly reduced the post-treatment RBC counts (25.22 %), the HB (25.19 %) level and the Hct (23.62 %), the white blood cell counts, (23.37 %) and the platelet counts (8.38 %) (all p < 0.05). The median depleted RBC volume was 1405.5 mL (range 1011.75-1677.5 mL). The median post-treatment target Hct was 40 % (range 40-45 %). The mean post-treatment Hct was in fact 47.57 % (6.54 %), which was higher than the target, and the mean Hct error ratio was 14.23 % (12.95 %). When the replacement solution was physiological saline, an adverse reaction (hypotension) occurred during 4.81 % of the 104 erythrocytapheresis sessions, but only in patients with a depleted RBC volume/weight (D/W) ≥ 25 mL/kg. No significant differences were observed between the Spectra Optia and COM.TEC blood cell separators. Erythrocytapheresis effectively reduces the RBC mass in patients with erythrocytosis.In rough terms, the post-treatment target Hct = the post-treatment Hct × 0.88, our research team has officially designated this formula as the 'Southwest Formula'. In the future, we will continue to expand the sample size to enhance the precision of this formula and better guide the clinical application of erythrocytapheresis.

Open article ↗



2024-08-31 | Impact of Phlebotomy on Quality of Life in Low-Risk Polycythemia Vera.

Polycythemia vera is an indolent myeloproliferative disorder that predisposes patients to venous and arterial thrombosis and can transform into myelofibrosis and acute myeloid leukemia. Consistent phlebotomy prevents life-threatening cerebrovascular and coronary artery disease and prolongs survival in low-risk polycythemia vera (patients under 60 years without thrombosis). However, despite its effectiveness in preventing serious complications, phlebotomy does not necessarily enhance the quality of life (QoL). This review assesses QoL issues associated with low-risk PV, explores alternative management strategies such as erythrocytapheresis, and discusses the roles of hydroxyurea, peginterferon, ruxolitinib, and other novel agents in potentially improving disease management and patient outcomes.

Open article ↗



2024-06-17 | A comparison between erythrocytapheresis and venesection for the treatment of JAK2-mutated polycythaemia.

JAK2-mutated polycythaemia vera (PV) is associated with reduced survival because of thrombotic events and haematological disease transformation. Therapeutic venesection has traditionally been used to lower haematocrit, but the technique of erythrocytapheresis has emerged over the last decade. To compare erythrocytapheresis with venesection as treatment for PV by assessing medical efficacy and financial viability. One hundred sixteen patients with PV who received red cell depletion therapy at Barwon Health between 2014 and 2021 were identified. The haematocrit drop after each session, interval between treatment times and number of sessions required to achieve a haematocrit <0.45 were compared with an independent t test. Thrombosis rates were compared with Pearson's chi-squared test. Cost-funding analysis was done by assessing the Weighted Inlier Equivalent Separation and National Weighted Activity Unit funding models. Patients treated with erythrocytapheresis achieved a greater haematocrit drop each treatment session (0.075 vs 0.03, P < 0.01), required fewer sessions to achieve a haematocrit <0.45 (1 vs 4, P < 0.01) and experienced fewer thrombotic complications (8.7% vs 32.1%, P = 0.02) than those treated with venesection. Cost-funding analysis demonstrated that erythrocytapheresis was more financially viable with a surplus of AU$297 per session compared to a deficit of AU$176 with venesection. Even if funding for venesection is increased, the cost of erythrocytapheresis may be mitigated by a lower number of procedures required per year (3.8 vs 5.3, P < 0.01). Erythrocytapheresis is more efficacious than venesection for the treatment of PV and is accompanied by rapid reductions in haematocrit and reduced thrombotic complications.

Open article ↗



proteins
2026-08-28 | Targeting the hepcidin-ferroportin axis in polycythemia vera: a complementary approach to clone-directed therapies.

Polycythemia vera (PV) is a clonal myeloproliferative neoplasm in which erythrocytosis, although driven by constitutive JAK2 signaling, remains dependent on iron availability. This dependency provides a rationale for therapeutic targeting of the hepcidin-ferroportin axis, whose modulation induces functional iron restriction and constrains erythropoiesis. The hepcidin mimetic rusfertide has shown durable hematocrit control and marked reduction of phlebotomy requirements across phase 2 and phase 3 studies, with predictable changes in systemic iron markers. However, current evidence is largely based on surrogate hematologic endpoints, and whether iron-directed strategies reduce thrombotic risk or modify disease trajectory remains undefined. Within this framework, iron metabolism can be viewed as a downstream, regulatable determinant of erythropoietic output, distinct from but integrated with clonal and inflammatory signaling. This review summarizes biological and clinical evidence on iron homeostasis in PV, focusing on the hepcidin-ferroportin axis and its integration with clone-directed therapies.

Open article ↗



2026-08-07 | Ropeginterferon alfa-2b in Polycythemia Vera: A systematic review and meta-analysis.

Ropeginterferon alfa-2b, a novel monopegylated interferon with improved pharmacokinetics, has emerged as a promising cytoreductive agent for managing polycythemia vera (PV). Despite increasing adoption, evidence synthesis of its efficacy and safety compared to standard care remains limited. The manuscript aimed to evaluate the efficacy of ropeginterferon alfa-2b in comparison to standard treatment options, including hydroxyurea and phlebotomy, in achieving complete hematologic response, partial molecular response (PMR), and reducing JAK2V617F allele burden in patients with PV. A systematic search of 4 databases was conducted up to April 2025, following PRISMA 2020 guidelines. Randomized controlled trials (RCTs) comparing ropeginterferon alfa-2b with standard therapies in PV patients were included. Meta-analyses were performed using random-effects models to derive odds ratios for dichotomous outcomes and mean differences (MDs) for continuous outcomes. Sensitivity and subgroup analyses were conducted, and risk of bias was assessed using RoB 2.0. Three RCTs comprising 522 patients were analyzed. Ropeginterferon alfa-2b showed no statistically significant advantage overall or over hydroxyurea for complete hematological response (CHR), PMR, or JAK2 allele burden reduction. However, subgroup analyses revealed significant benefits over phlebotomy alone in all 3 outcomes: CHR (odds ratio [OR] 3.05; 95% confidence interval [CI]: 1.36-6.80; P = .007), PMR (OR 36.34; 95% CI: 2.11-625.93; P = .01), and allele burden reduction (MD -13.70; 95% CI: -19.24 to -8.16; P < .00001). Ropeginterferon alfa-2b demonstrates no statistically significant difference compared to hydroxyurea, but gives better outcomes over phlebotomy in short-term efficacy for PV management. Its favorable molecular and hematologic outcomes support its role as a disease-modifying therapy, particularly in low-risk patients. However, larger and longer-term trials are needed to confirm these benefits across broader populations.

Open article ↗



2026-07-16 | Successful Topical Treatment of Hydroxyurea-Induced Ulcers Without Drug Discontinuation: A Case Report.

Hydroxyurea, an antineoplastic agent, is widely used to treat essential thrombocythemia and polycythemia vera. Although hydroxyurea-induced skin ulcers are uncommon, they are a recognized long-term adverse effect. Current management generally recommends discontinuation of hydroxyurea as the mainstay of treatment; however, drug withdrawal may aggravate the underlying hematologic disease. We report a case of bilateral medial malleolar ulcers associated with hydroxyurea therapy in a 65-year-old man with essential thrombocythemia, who showed marked improvement after two months of topical treatment with recombinant bovine basic fibroblast growth factor (rb-bFGF) gel, without discontinuation of hydroxyurea. Complete healing was confirmed at 25-month follow-up, while hematologic disease control was maintained. This case suggests that localized wound care with topical rb-bFGF may represent a feasible therapeutic option in selected patients when hydroxyurea discontinuation is not feasible.

Open article ↗



2026-05-03 | Hematologic and molecular response to ropeginterferon alfa-2b in patients with polycythemia vera: a systematic review and meta-analysis.

Ropeginterferon alfa-2b is an interferon used in the treatment of myeloproliferative neoplasms, particularly polycythemia vera. Its efficacy in achieving hematologic and molecular responses has been demonstrated in clinical trials, but pooled data on long-term outcomes and sustained response remain limited. This systematic review and meta-analysis aimed to evaluate the hematologic and molecular response over 36 months. PubMed, Scopus, Science Direct, and Google Scholar databases were searched to identify studies reporting hematologic and molecular responses to ropeginterferon alfa-2b. Studies were included if they provided data on complete hematologic response (CHR) and JAK2V617F variant allele frequency (VAF) reduction. Pooled proportions and mean reductions were calculated using random-effects models. The pooled proportion of CHR increased progressively from 0.19 (95% CI: 0.04-0.57) at 3 months to 0.73 (95% CI: 0.17-0.97) at 36 months. Molecular response, measured by VAF reduction, deepened over time from - 7.33 (95% CI: -9.85 to -4.81) at 3 months to -54.90 (95% CI: -65.61 to -43.99) at 36 months. Subgroup analyses revealed significant variability in response rates, particularly in early follow-up periods. Ropeginterferon alfa-2b achieves significant and sustained hematologic and molecular responses over 36 months. This makes it a promising treatment for polycythemia vera. While variability in early responses needs further investigation, the sustained long-term efficacy compared to hydroxyurea supports its use in clinical practice. Future studies should focus on identifying predictors of response and optimizing treatment protocols to maximize patient outcomes.

Open article ↗



2026-04-11 | Ropeginterferon dose-escalation strategies in polycythemia vera: a systematic review and meta-analysis

Abstract Background Ropeginterferon alfa-2b is increasingly used as a long-acting interferon therapy for polycythemia vera (PV), providing hematologic and molecular benefits. However, clinical studies have implemented different dose-escalation strategies, and their impact on outcomes has not been systematically evaluated. Methods A systematic search of PubMed, Embase, and the Cochrane Library (September 24, 2025) identified studies reporting clinical outcomes of ropeginterferon in PV. Nine studies met eligibility criteria. Two reviewers independently extracted data, and meta-analyses were conducted using random-effects models. Subgroup analyses compared slow dose-up (SDU) and rapid dose-up (RDU) regimens at 1-, 2-, and 3-year follow-up when available. Results The pooled 1-year complete hematologic response (CHR) rate was 0.59 (95% CI, 0.47–0.71). RDU regimens yielded significantly higher CHR than SDU at both 1 year (0.67 vs. 0.41; p < 0.001) and 2 years (0.75 vs. 0.63; p = 0.038). Molecular response (MR) also favored RDU at 1 year (0.59 vs. 0.36; p < 0.001), with differences diminishing at 2 years. The pooled 1-year reduction in JAK2 V617F allele burden was − 22.2% (95% CI, − 34.2% to − 10.2%; p < 0.001). Safety outcomes were favorable, with low rates of thrombosis (4%), serious adverse events (5%), and treatment discontinuation (7%). Conclusions Ropeginterferon alfa-2b provides meaningful hematologic and molecular responses with an acceptable safety profile in PV. Rapid dose-escalation facilitates earlier CHR and MR without increasing toxicity, suggesting titration speed as an important determinant of early treatment optimization.

Open article ↗



antibodies
2026-08-19 | Myeloproliferative Neoplasms.

Classic myeloproliferative neoplasms, including essential thrombocythemia, polycythemia vera, and primary myelofibrosis, are chronic, clonal hematopoietic stem-cell disorders. These disorders are driven by gain-of-function mutations in the genes Janus kinase 2 (JAK2), calreticulin (CALR), or the thrombopoietin receptor (MPL) that activate cytokine signaling. These mutations arise decades before clinical disease develops and confer a clonal advantage that is further shaped by comutations in epigenetic, splicing, or signaling genes. Inflammation enhances clonal dominance, favoring the development of myelofibrosis and thrombotic complications. Disease evolution may culminate in secondary acute myeloid leukemia, which has a poor prognosis. Current therapies primarily aim to control symptoms, thrombosis, and splenomegaly, but they have limited disease-modifying effects, except for pegylated interferon alfa and JAK2 inhibitors in some patients. Emerging therapies that selectively target mutant CALR and JAK2 V617F using immunotherapy and selective inhibitors could be a breakthrough in the treatment of persons with myeloproliferative neoplasms, with the expectation of achieving durable disease modification and potentially clonal eradication.

Open article ↗



2026-04-29 | A Phase 1 Randomized, Double-Blind, Placebo-Controlled Single and Multiple Ascending Dose Study of DISC-3405, a Novel Recombinant Humanized Monoclonal Antibody Targeting TMPRSS6, in Adult Healthy Volunteers.

Hepcidin is the central regulator of iron homeostasis, controlling iron sequestration and dietary iron absorption. Transmembrane serine protease 6 (TMPRSS6) suppresses hepcidin via the bone morphogenetic protein/small mothers against decapentaplegic (BMP/SMAD) pathway by cleaving the co-receptor hemojuvelin. DISC-3405 is a novel humanized monoclonal antibody that enhances hepcidin expression by inhibiting TMPRSS6, thereby promoting iron restriction. This Phase 1 study evaluated the safety/tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of DISC-3405 or placebo in 56 healthy participants. DISC-3405 (37.5 to 300 mg) or placebo was administered subcutaneously (SC) or intravenously (IV). DISC-3405 was well tolerated. No deaths, serious adverse events, or participant discontinuations occurred. Most treatment-emergent adverse events were Grade 1 (mild) in severity, with 2 participants reporting Grade 2 (moderate) events following single dosing and no Grade 3/4 (severe/life-threatening) events reported. Median time to maximum plasma concentration was ≈96 to 168 h. Elimination half-life rose from 130 h at 37.5 mg to 265 h at 300 mg, with a clinically relevant half-life of ≈11 days. Absolute bioavailability was 39.7% (75 mg SC vs. IV). Minor accumulation occurred with repeat 4-week dosing of two doses, and PK was greater than dose proportional. DISC-3405 increased hepcidin-25 and reduced serum iron and transferrin saturation across dose levels. Single and repeated dosing of DISC-3405 produced reductions in reticulocyte hemoglobin, hemoglobin, and hematocrit. Overall, DISC-3405 was well tolerated with PK/PD data supporting further development for patients who could benefit from iron restriction, such as those with polycythemia vera.

Open article ↗



2025-11-30 | Mesenchymal stromal cells secretory pattern contributes to oncoinflammatory bone marrow microenvironment in polycythemia vera.

Polycythemia vera is a myeloproliferative neoplasm marked by an increased proliferation of erythroid mature and precursors cells in bone marrow and peripheral blood. The pathophysiology is linked to the presence of the JAK2 driver mutation, epigenetic deregulation, and alterations in the bone marrow hematopoietic niche. Multipotent mesenchymal stromal cells (MSC) in the bone marrow, which are crucial for maintenance and development of hematopoietic stem cells, play a role in the communication between neoplastic cells and resident bone marrow cells by releasing various mediators that either suppress or promote tumor progression. These mediators include several essential immunomodulatory molecules, pro-angiogenic and growth factors. We hypothesized that MSC from polycythemia vera patients (Patient Group) would exhibit distinct properties compared to those from healthy donors (Control Group), thereby influencing the hematopoietic niche and contributing to disease pathogenesis. This study characterized MSC from patients, focusing on their secretory, proteomic, and phenotypic properties. MSC from the Patient and Control Groups had similar immunophenotypes and multipotentiality. However, MSC from the Patient Group exhibited reduced immunomodulatory properties, and released distinct soluble immune and angiogenic mediators when compared with the Control Group. Global proteomic analysis revealed that MSC from patients presented upregulated expressions of FAM175B, VP526A, CTTN, MAP4, BAX, and TPD52L2 but a downregulated TNC expression. These results indicate that MSC contribute to the inflammation pattern in the hematopoietic niche. The secretory and proteomic profile of MSC from patients, indicate that these cells may influence immune cell function, induce neoangiogenesis, and alter cell-to-cell interactions within the bone marrow, thereby fostering a pro-tumor microenvironment and favoring disease pathogenesis. These findings highlight the potential of targeting MSC-mediated pathways as a therapeutic strategy in polycythemia vera.

Open article ↗



2025-10-27 | Unveiling CD177: a key player in tumors, autoimmune diseases, and inflammatory disorders.

CD177, also referred to as human neutrophil antigen NB1 or polycythemia rubra vera-1, is a glycosylphosphatidylinositol-anchored glycoprotein with a molecular weight of approximately 58-64 kDa, predominantly expressed in neutrophils, neutrophilic myelocytes, and metamyelocytes. While extensive research has focused on the role of CD177 in neutrophils, where it is implicated in transendothelial migration, cellular viability, and bactericidal activities, its functions outside of neutrophils remain largely unexplored. Under inflammatory conditions, CD177 expression on neutrophils is significantly upregulated, facilitating their migration to sites of inflammation. CD177+ neutrophils have been shown to accumulate in inflamed tissues and modulate the release of inflammatory mediators and the formation of neutrophil extracellular traps (NETs), correlating with the severity of inflammation in conditions such as inflammatory bowel disease (IBD) and acute respiratory distress syndrome (ARDS). An imbalance in CD177+ neutrophils has been identified as a critical pathogenic mechanism in vascular inflammation, tissue necrosis, and systemic lupus erythematosus (SLE). Furthermore, CD177 expression on neutrophils, epithelial cells, and regulatory T cells in solid tumors has been associated with tumor invasion, disease stage, therapeutic responses, and patient survival in various cancers, including gastric, breast, and colorectal cancer (CRC). Nevertheless, elucidating the intricate mechanisms underlying CD177's role in these diseases remains a significant challenge. In light of these findings, we present a comprehensive review of recent literature concerning the role of CD177 in tumors, inflammatory processes, and autoimmune diseases, with a particular focus on its mediating effects on neutrophil recruitment, transepithelial migration, and the activation of CD177-positive neutrophils, along with the functional implications of CD177 expression beyond neutrophils. A deeper understanding of CD177 may pave the way for the development of novel therapeutic strategies and the assessment of disease prognosis.

Open article ↗



2024-12-10 | JAK2 mutations in polycythemia vera: from molecular origins to inflammatory pathways and clinical implications

Summary Polycythemia vera (PV) is a myeloproliferative neoplasm primarily driven by mutations in the JAK2 gene, most notably the V617F mutation, which occurs in nearly 97% of cases. This gain-of-function mutation overactivates the JAK-STAT pathway, a critical factor in developing the PV phenotype by stimulating excessive proliferation of the erythroblastic lineage. Diagnostic methods for PV focus on detecting the JAK2 mutation—primarily through polymerase chain reaction (PCR) and next-generation sequencing, which are essential for distinguishing PV from other disorders. The variant allele frequency (VAF) of JAK2 V617F also serves as an important prognostic marker, with higher VAF linked to both increased thrombotic risk and disease progression to myelofibrosis or acute leukemia. Thus, managing allele burden is central to treatment strategies. Given the genetic complexity of PV, personalized treatment approaches are essential. Current therapies focus on JAK2 signaling, with ropeginterferon alfa-2b and JAK inhibitors as primary or secondary treatments to reduce clonal expansion and control inflammation, and aspirin to prevent thrombotic events. Emerging treatments are exploring anti-inflammatory strategies, such as anti-IL-1β antibodies, and agents targeting iron metabolism to maintain hematocrit levels without phlebotomy, potentially improving quality of life. Overall, reducing JAK2 V617F burden and controlling inflammation are crucial for managing PV progression and improving patient outcomes, with ongoing research refining these therapeutic avenues to enhance long-term strategies.

Open article ↗



other
2026-08-18 | Sapablursen for Erythrocytosis Control in Patients with Polycythemia Vera.

Polycythemia vera is characterized by erythrocytosis and increased risk of thrombosis. Sapablursen is an antisense oligonucleotide that suppresses transmembrane serine protease 6 (TMPRSS6), increases hepcidin production, and reduces iron availability for erythropoiesis. IMPRSSION; an ongoing phase 2a, randomized, open-label study includes patients meeting 2016 WHO criteria for polycythemia vera, requiring ≥3 phlebotomies within 6 months of screening and ≥1 phlebotomy within the last 12 weeks. Cohort A (120 or 80 mg) and Cohort B (40 mg) received sapablursen subcutaneously once every 4 weeks (Q4W). The primary efficacy endpoint was the reduction in phlebotomy frequency from baseline to weeks 17-37 in patients who received ≥1 dose. Forty-nine patients received ≥1 sapablursen dose (median age 61 years; 82% male). The baseline mean±SD weekly phlebotomy rate was 0.15±0.07 in Cohort A; 0.17±0.07 in Cohort B and was reduced by -0.10 (95%CI, -0.13, -0.07; n=32;p<0.0001) in Cohort A; -0.10 (95%CI, -0.14, -0.06; n=17;p=0.0001) in Cohort B. Sapablursen reduced the median (IQR) number of phlebotomies from 5.0 (3.0-6.0,Cohort A; 3.5-6.5,Cohort B) at baseline (26-weeks) to 0 (0-1.0) in the efficacy evaluation window (20-weeks) in Cohort A and 1.5 (0-2.5) in Cohort B. Most adverse events were mild or moderate; anemia and fatigue were most common. The mean change in MPN-SAF-TSS at week 37 was -6.21 points (95%CI: -10.56, -1.85, p=0.0052) in Cohort A; -2.71 points in Cohort B (95% CI: -8.33, 2.91, p=0.34). Sapablursen reduced phlebotomy need, improved symptoms, and was safe and well-tolerated in patients with polycythemia vera. (Funded by Ionis Pharmaceuticals; ClinicalTrials.gov: NCT05143957).

Open article ↗



2026-07-31 | A Therapeutic Dilemma: Catastrophic ST-Elevation Myocardial Infarction Following Antiplatelet Therapy Interruption in a Patient With JAK2-Positive Polycythemia Vera.

Polycythemia vera is associated with a thrombotic-hemorrhagic paradox. We report a 75-year-old woman with recurrent ST-elevation myocardial infarction and stent thrombosis after premature dual antiplatelet therapy interruption. Revascularization was successful, and eptifibatide bridging enabled safe surgery. This case highlights the risks of interruption and the role of bridging therapy.

Open article ↗



2025-12-02 | Recent advancements in aptamer-mediated theranostics in the management of hematological disorders.

Increasing trends in the incidence rate and death rate in hematological disorders, specifically hematological malignancies, indicate the need for advancements in therapeutic approaches. Various hematological disorders include hemophilia, leukemia, lymphoma, myeloma, thrombocytopenia, sickle cell anemia, thalassemia, polycythemia vera, and aplastic anemia. Chemotherapy, cytoreductive therapy, and monoclonal antibodies are typically used for the treatment of hematological disorders. Stem cell transplantation is also performed for this purpose. However, these conventional therapeutic approaches exhibit several drawbacks, such as nonspecificity and side effects. Aptamers, being RNA or DNA oligonucleotides, selectively bind to a specific complementary molecule and serve as strong therapeutic components, offering significant theranostic implications and numerous therapeutic and diagnostic alternatives for hematological disorders. This article explains the systematic evolution of ligands through exponential enrichment, also known as the SELEX process of aptamer selection, their mechanism of action, and their wide range of applications. Moreover, it discusses the various advanced approaches for aptamer modifications to enhance their flexibility, expanding their applicability. This review article focuses on the recent updates in the application of aptamers in different hematological disorders, highlighting their potential in the therapy and diagnosis of hematological diseases.

Open article ↗



2025-11-03 | Evaluation of the novel TMPRSS6 antisense inhibitor sapablursen for treatment of polycythemia vera: Results of the imprssion clinical trial

Abstract Background: Polycythemia vera (PV) is characterized by excessive erythrocytosis and elevated hematocrit (Hct), which is associated with increased risk of thrombotic events. Controlling Hct levels (&lt;45%) is a key therapeutic goal to reduce thrombotic events. Sapablursen (ISIS 702843) is a liver-directed, ligand-conjugated antisense oligonucleotide that suppresses transmembrane serine protease 6 (TMPRSS6) to enhance hepcidin production thereby restricting iron availability and reduced erythrocytosis. We are reporting the topline results of the IMPRSSION study (NCT05143957), an ongoing global, open-label phase 2 trial evaluating the safety and efficacy of sapablursen for Hct control and reducing phlebotomy rate in patients with PV. Methods: Eligible patients met 2016 WHO diagnostic criteria for PV, were required to have &gt;3 phlebotomies within six months prior to screening, including &gt;1 phlebotomy in the last 12 weeks. There were no exclusions for HCT prior to randomization. Patients received monthly subcutaneous doses of sapablursen in Cohort A (high dose) or Cohort B (low dose), during a 37-week treatment period. The primary efficacy endpoint was the reduction in the frequency of phlebotomy during the last 20 weeks of the treatment period (Week 17-37) compared to baseline (defined as the mean weekly phlebotomy rate during the six months prior to screening through the first dose of sapablursen). Phlebotomy was performed when Hct levels were ≥45% or at the investigator's discretion, confirmation of Hct was not required for phlebotomy. Serial assessments of serum hepcidin, TSAT and ferritin were conducted. The 10-item Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (MPN-SAF-TSS) assessed the change in symptoms from baseline to Week 37. Results: Forty-nine (49) patients received at least one dose of sapablursen (full analysis set) in either Cohort A (n=32) or Cohort B (n=17). The median age was 61 years, 40 (82%) were male, and 29 (59%) classified as high risk. The primary endpoint was met at both dose levels. The weekly phlebotomy rate (mean±SD) decreased from baseline of 0.15±0.07 (~7.8/yr) to 0.05±0.09 (~2.6/yr) during the primary endpoint window (Week 17-37) in Cohort A (n=32, p&lt;0.0001; 95%CI, -0.13, -0.07), and from 0.17±0.07 (~8.9/yr) to 0.07±0.07 (~3.6/yr) in Cohort B (n=17, p=0.0001; 95%CI, -0.14, -0.06). The mean MPN-SAF-TSS was reduced at Week 37 by 32% in Cohort A (change from baseline LSM -6.2, p=0.005) and 11% in Cohort B (change from baseline LSM -2.7, p=0.344). The proportion of patients with Hct control (&lt;45%) without phlebotomy from week 17 to 37 in Cohort A and B was 53% (17/32) and 35% (6/17), respectively. Serum hepcidin was increased from baseline values of 0.25±0.6 to 5.05±4.7 nM at Week 13 in Cohort A (p&lt;0.0001) and from 0.68±1.7 to 2.06±3.6 nM in Cohort B (p=0.0142). A sustained low TSAT was observed between Weeks 17-37 (6.0±2.1% and 5.5±2.0% in Cohort A and 8.9±5.0% and 7.0±3.4% in Cohort B). Serum ferritin increased over time from 18±22 ng/mL and 28±58 ng/mL at baseline in Cohort A and B, respectively, to 44±47 ng/mL and 41±85 ng/mL at Week 37, respectively. Sapablursen was generally safe and well-tolerated. The incidence of injection site reactions was 12.2% (6/49). Injection site reactions did not recur following multiple injections, were not progressive and resolved spontaneously. There was one death on study due to transformation to AML which was deemed as not related to the study drug. Conclusions: Treatment of PV patients with sapablursen increased serum hepcidin, controlled Hct, reduced phlebotomy need and improved quality of life in a dose-dependent manner. These findings highlight the potential of sapablursen as a therapeutic approach in PV and support further development.

Open article ↗



2024-01-22 | Idiopathic erythrocytosis: a germline disease?

Polycythemia Vera (PV) is typically caused by V617F or exon 12 JAK2 mutations. Little is known about Polycythemia cases where no JAK2 variants can be detected, and no other causes identified. This condition is defined as idiopathic erythrocytosis (IE). We evaluated clinical-laboratory parameters of a cohort of 56 IE patients and we determined their molecular profile at diagnosis with paired blood/buccal-DNA exome-sequencing coupled with a high-depth targeted OncoPanel to identify a possible underling germline or somatic cause. We demonstrated that most of our cohort (40/56: 71.4%) showed no evidence of clonal hematopoiesis, suggesting that IE is, in large part, a germline disorder. We identified 20 low mutation burden somatic variants (Variant allelic fraction, VAF, < 10%) in only 14 (25%) patients, principally involving DNMT3A and TET2. Only 2 patients presented high mutation burden somatic variants, involving DNMT3A, TET2, ASXL1 and WT1. We identified recurrent germline variants in 42 (75%) patients occurring mainly in JAK/STAT, Hypoxia and Iron metabolism pathways, among them: JAK3-V722I and HIF1A-P582S; a high fraction of patients (48.2%) resulted also mutated in homeostatic iron regulatory gene HFE-H63D or C282Y. By generating cellular models, we showed that JAK3-V722I causes activation of the JAK-STAT5 axis and upregulation of EPAS1/HIF2A, while HIF1A-P582S causes suppression of hepcidin mRNA synthesis, suggesting a major role for these variants in the onset of IE.

Open article ↗



Access all drug discovery papers and probability of success in trials forecasts:

Access all drug discovery papers and probability of success in trials forecasts:

Drug Discovery Landscape

23 orphan drug designations for Polycythemia vera, including 4 approved therapies.

23 orphan drug designations for Polycythemia vera, including 4 approved therapies.

Drug

Therapy type

Orphan designation

Clinical trial status

Sponsor

recombinant fully human IgG1 monoclonal antibody

antibodies

FDA
2026-01-22

Phase II
Ongoing

mAbTree Biologics AG

synthetic 19-mer peptide nucleic acid oligomer consisting of two guanine bases possessing a 5-aminopentyl modification, four adenine bases with a 6-aminohexyl moiety, and a fluorenylethoxycarbonyl (Fethoc) group at the 5' terminal end of the sequence

oligonucleotides

FDA
2025-08-26

—

Vanda Pharmaceuticals Inc.

synthetic 2-O-methoxyethyl phosphorothioate oligoribonucleotide sodium salt consisting of 19 nucleotide residues with the sequence 5'-AMeUAGMeUMeUMeCAMeUAAMeUMeCMeUGGAGA-3'

oligonucleotides

FDA
2024-12-19

—

Vanda Pharmaceuticals Inc

Divesiran

RNAs

EMA
2024-12-13

Phase I/II
Ongoing

Silence Therapeutics GmbH

Sapablursen

oligonucleotides

FDA
2024-08-05

Phase III
Ongoing

Deciphera Pharmaceuticals, LLC

recombinant humanized monoclonal antibody targeting transmembrane serine protease matripase-6

antibodies

FDA
2024-02-08

Phase II
Ongoing

Disc Medicine, Inc.

Synthetic double-stranded siRNA oligonucleotide directed against TMPRSS6 mRNA and covalently linked to a ligand containing 3 N-acetylgalactosamine residues

RNAs

FDA
2022-02-24

Phase I/II
Ongoing

Silence Therapeutics plc

1-(3-methylbutanoyl)-l-aspartyl-l-threonyl-l-histidyl-l-phenylalanyl-l-prolyl-(l-cystinyl-l-isoleucyl-[(n6-(s)-4-carboxy-4-palmitamidobutanoyl)-l-lysinyl]-l-phenylalanyl-l-glutamyl-l-prolyl-l-arginyl-l-serinyl-l-lysinyl-l-glycinyl-l-cystinyl)-l-lysinamide, disulfide, acetate

small molecules

EMA
2020-10-19

Phase III
Ongoing

Takeda Pharmaceuticals International AG Ireland Branch

rusfertide [Mimrylo]

peptides

FDA
2020-06-12

Approved
2026-08-28

Takeda Development Center Americas, Inc.

idasanutlin

small molecules

FDA
2017-11-29

Phase II
Terminated

Hoffmann-La Roche Inc.

Givinostat

small molecules

FDA
2017-09-28

Phase III
Ongoing

Italfarmaco SpA

Ruxolitinib phosphate [Jakavi]

small molecules

EMA
2014-02-19

Phase III
Ongoing

Novartis Europharm Limited

Fedratinib

small molecules

FDA
2013-03-21

Phase III
Completed

Impact Biomedicines

ropeginterferon alfa-2b-njft [Besremi]

proteins

FDA
2012-04-02

Approved
2021-11-12

PharmaEssentia

Chimeric locked nucleic acid-deoxynucleoside phosphorothioate-linked oligonucleotide directed against microRNA-451

oligonucleotides

EMA
2012-01-11

Phase I/II
Ongoing

[INACTIVE] Viridian Therapeutics Europe Limited

Ropeginterferon alfa-2b [Besremi]

proteins

EMA
2011-12-09

Phase III
Terminated

[INACTIVE] Aop Orphan Pharmaceuticals GmbH

inhibitor of microRNA-451

RNAs

FDA
2011-02-04

Phase III
Ongoing

miRagen Therapeutics, Inc.

ruxolitinib [Jakafi XR]

small molecules

FDA
2010-03-26

Approved
2026-05-01

Incyte Corporation

ruxolitinib [Jakafi]

small molecules

FDA
2010-03-26

Approved
2014-12-04

Incyte Corporation

Givinostat

small molecules

EMA
2010-02-03

Phase III
Ongoing

Italfarmaco S.p.A.

Acetylsalicylic acid

small molecules

EMA
2004-07-29

—

Bayer AG

natural human lymphoblastoid interferon-alpha

proteins

FDA
2002-11-18

—

Amarillo Biosciences, Inc.

Anagrelide

small molecules

FDA
1985-06-11

Phase III
Terminated

Roberts Pharmaceutical Corp.

“Terminated” – programs with discontinued clinical trials, or with no updates reported for 5 years after completion or 12 years after the last trial started.

Explority AI logo

228 Park Ave S,
New York, USA.

At Explority, we build first-of-its-kind AI to bring clarity to the earliest and riskiest stages of pharmaceutical research by forecasting which therapies are most likely to succeed. Explority AI web and mobile applications are properties of the Explority AI Inc., a company registered in the United States (File No. 10320493).
For all questions: support@explority.ai

Copyright © 2026 Explority AI Inc.

Explority AI logo

228 Park Ave S,
New York, USA.

At Explority, we build first-of-its-kind AI to bring clarity to the earliest and riskiest stages of pharmaceutical research by forecasting which therapies are most likely to succeed. Explority AI web and mobile applications are properties of the Explority AI Inc., a company registered in the United States (File No. 10320493).
For all questions: support@explority.ai

Copyright © 2026 Explority AI Inc.

Explority AI logo

228 Park Ave S,
New York, USA.

At Explority, we build first-of-its-kind AI to bring clarity to the earliest and riskiest stages of pharmaceutical research by forecasting which therapies are most likely to succeed. Explority AI web and mobile applications are properties of the Explority AI Inc., a company registered in the United States (File No. 10320493).
For all questions: support@explority.ai

Copyright © 2026 Explority AI Inc.